Marrow infiltrating lymphocytes: Their role in adoptive immunotherapy

Research output: Contribution to journalArticle

Abstract

The clinical results achieved with immunotherapy in the past few years have now firmly established it within the cancer armamentarium. Our group has explored a novel approach to adoptive T-cell therapy utilizing marrow-infiltrating lymphocytes (MILs) initially developed with the concept of utilizing a population of T cellswith a higher endogenous tumor specificity. Marrow-infiltrating lymphocytes are antigen-experienced T cells that home to and remain in the bone marrow (BM) because of the unique biology of the BMmicroenvironment.Marrow-infiltrating lymphocytes can easily be obtained from the BM and can be expanded to demonstrate enhanced antigen specificity. Current clinical trials utilize MILs for patients with myeloma as well as patients with relapsed disease following an allogeneic transplant. Ongoing preclinicalwork is currently evaluating MILs for use in solid cancers as well as pediatric cancers. The examination of a MIL as a source cell for chimeric antigen receptor T or transgenic cell receptor is also in the preclinical stages. Until now, for both chimeric antigen receptor T-cell therapy and transgenic cell receptor T-cell therapy, the target cell of choice has included peripheral blood. The unique antigen-experienced properties of MILs may make them the ideal source of cell for gene modification strategies. Therefore, MILs are a distinctive set of T cells that have been shaped by the unique BM microenvironment and may play a future role as a novel immunotherapy for hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)501-505
Number of pages5
JournalCancer Journal (United States)
Volume21
Issue number6
StatePublished - 2015

Fingerprint

Adoptive Immunotherapy
Bone Marrow
Lymphocytes
Cell- and Tissue-Based Therapy
T-Cell Antigen Receptor
T-Lymphocytes
Antigens
Immunotherapy
Neoplasms
Antigen Receptors
Hematologic Neoplasms

Keywords

  • Bone marrow
  • Marrow-infiltrating lymphocytes (MILs)
  • T cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Marrow infiltrating lymphocytes : Their role in adoptive immunotherapy. / Noonan, Kimberly; Borrello, Ivan M.

In: Cancer Journal (United States), Vol. 21, No. 6, 2015, p. 501-505.

Research output: Contribution to journalArticle

@article{6bca633229f94a0d98cca6f6d17b11a3,
title = "Marrow infiltrating lymphocytes: Their role in adoptive immunotherapy",
abstract = "The clinical results achieved with immunotherapy in the past few years have now firmly established it within the cancer armamentarium. Our group has explored a novel approach to adoptive T-cell therapy utilizing marrow-infiltrating lymphocytes (MILs) initially developed with the concept of utilizing a population of T cellswith a higher endogenous tumor specificity. Marrow-infiltrating lymphocytes are antigen-experienced T cells that home to and remain in the bone marrow (BM) because of the unique biology of the BMmicroenvironment.Marrow-infiltrating lymphocytes can easily be obtained from the BM and can be expanded to demonstrate enhanced antigen specificity. Current clinical trials utilize MILs for patients with myeloma as well as patients with relapsed disease following an allogeneic transplant. Ongoing preclinicalwork is currently evaluating MILs for use in solid cancers as well as pediatric cancers. The examination of a MIL as a source cell for chimeric antigen receptor T or transgenic cell receptor is also in the preclinical stages. Until now, for both chimeric antigen receptor T-cell therapy and transgenic cell receptor T-cell therapy, the target cell of choice has included peripheral blood. The unique antigen-experienced properties of MILs may make them the ideal source of cell for gene modification strategies. Therefore, MILs are a distinctive set of T cells that have been shaped by the unique BM microenvironment and may play a future role as a novel immunotherapy for hematologic malignancies.",
keywords = "Bone marrow, Marrow-infiltrating lymphocytes (MILs), T cells",
author = "Kimberly Noonan and Borrello, {Ivan M}",
year = "2015",
language = "English (US)",
volume = "21",
pages = "501--505",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "6",

}

TY - JOUR

T1 - Marrow infiltrating lymphocytes

T2 - Their role in adoptive immunotherapy

AU - Noonan, Kimberly

AU - Borrello, Ivan M

PY - 2015

Y1 - 2015

N2 - The clinical results achieved with immunotherapy in the past few years have now firmly established it within the cancer armamentarium. Our group has explored a novel approach to adoptive T-cell therapy utilizing marrow-infiltrating lymphocytes (MILs) initially developed with the concept of utilizing a population of T cellswith a higher endogenous tumor specificity. Marrow-infiltrating lymphocytes are antigen-experienced T cells that home to and remain in the bone marrow (BM) because of the unique biology of the BMmicroenvironment.Marrow-infiltrating lymphocytes can easily be obtained from the BM and can be expanded to demonstrate enhanced antigen specificity. Current clinical trials utilize MILs for patients with myeloma as well as patients with relapsed disease following an allogeneic transplant. Ongoing preclinicalwork is currently evaluating MILs for use in solid cancers as well as pediatric cancers. The examination of a MIL as a source cell for chimeric antigen receptor T or transgenic cell receptor is also in the preclinical stages. Until now, for both chimeric antigen receptor T-cell therapy and transgenic cell receptor T-cell therapy, the target cell of choice has included peripheral blood. The unique antigen-experienced properties of MILs may make them the ideal source of cell for gene modification strategies. Therefore, MILs are a distinctive set of T cells that have been shaped by the unique BM microenvironment and may play a future role as a novel immunotherapy for hematologic malignancies.

AB - The clinical results achieved with immunotherapy in the past few years have now firmly established it within the cancer armamentarium. Our group has explored a novel approach to adoptive T-cell therapy utilizing marrow-infiltrating lymphocytes (MILs) initially developed with the concept of utilizing a population of T cellswith a higher endogenous tumor specificity. Marrow-infiltrating lymphocytes are antigen-experienced T cells that home to and remain in the bone marrow (BM) because of the unique biology of the BMmicroenvironment.Marrow-infiltrating lymphocytes can easily be obtained from the BM and can be expanded to demonstrate enhanced antigen specificity. Current clinical trials utilize MILs for patients with myeloma as well as patients with relapsed disease following an allogeneic transplant. Ongoing preclinicalwork is currently evaluating MILs for use in solid cancers as well as pediatric cancers. The examination of a MIL as a source cell for chimeric antigen receptor T or transgenic cell receptor is also in the preclinical stages. Until now, for both chimeric antigen receptor T-cell therapy and transgenic cell receptor T-cell therapy, the target cell of choice has included peripheral blood. The unique antigen-experienced properties of MILs may make them the ideal source of cell for gene modification strategies. Therefore, MILs are a distinctive set of T cells that have been shaped by the unique BM microenvironment and may play a future role as a novel immunotherapy for hematologic malignancies.

KW - Bone marrow

KW - Marrow-infiltrating lymphocytes (MILs)

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=84948429704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948429704&partnerID=8YFLogxK

M3 - Article

C2 - 26588683

AN - SCOPUS:84948429704

VL - 21

SP - 501

EP - 505

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 0765-7846

IS - 6

ER -